Litecoin, HBAR and more crypto ETFs ‘at the goal line’ as shutdown sits in the backdrop, analysts say
Quick Take On Tuesday, Canary Capital filed an amended registration statement for its Canary HBAR ETF, disclosing its ticker symbol as HBR and designating a 0.95% sponsor fee. The SEC is weighing heaps of crypto ETF proposals from ones tracking DOGE to XRP to LTC.
A new filing for an exchange-traded fund tracking HBAR has revealed key details that analysts say could signal it's inching closer to receiving the U.S. Securities and Exchange Commission's sign-off.
On Tuesday, Canary Capital filed an amended registration statement for its Canary HBAR ETF, disclosing its ticker symbol as HBR and designating a 0.95% sponsor fee. The firm also has a Litecoin ETF in development, which will be listed under the ticker symbol LTCC, with a 0.95% sponsor fee.
Bloomberg Senior ETF analyst Eric Balchunas says those details are usually the last thing to be updated before "go-time."
"With shutdown tho who knows but these docs look pretty finalized to me," Balchunas said in a post on Tuesday on X. He also said the 0.95% fee is "pricey" compared to spot Bitcoin ETFs, "but pretty normal to see higher fees for areas that are new to being ETF-ed and increasingly niche."
Bloomberg Intelligence analyst James Seyffart shared a similar sentiment: "Feels like Litecoin and HBAR ETFs are at the goal line here."
The SEC is weighing heaps of crypto ETF proposals from ones tracking DOGE to XRP to LTC. Those had been filed over the past year by firms in the wake of a friendlier regulatory environment for digital assets under the Trump administration.
However, a government shutdown in the U.S. has sort of thrown a temporary wrench into those plans. The SEC was poised to allow crypto ETFs to launch imminently, but the shutdown has since put the agency on ice after Congress failed to reach a deal on funding. It's unclear when the government will reopen, but it could be weeks or closer to a month.
The SEC is currently working under an operations plan whereby it has an "extremely limited number of staff members available to respond to emergency situations," according to that guidance .
Also on Tuesday, global investment firm GraniteShares filed for multiple leveraged ETFs, including Solana, XRP, and Ethereum. Last week, firms also filed for dozens and dozens of similar funds.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
